TLR4 as a therapeutic target for respiratory and neurological complications of SARS-CoV-2

Expert Opin Ther Targets. 2021 Jun;25(6):491-508. doi: 10.1080/14728222.2021.1918103. Epub 2021 Apr 28.

Abstract

Introduction: The COVID-19 pandemic remains aglobal challenge. While there are mRNA agents on the horizon as apotential prevention, adefinitive drug therapy is an unmet medical need. The hyperinflammatory response, known as the 'cytokine storm', is chiefly responsible for complications and deaths. The binding of spike-glycoprotein of SARS-CoV-2 to TLR4 receptors has been documented in several studies and has been found to play arole in hyperinflammation; hence, there is an interest in TLR4 as apotential drug target.Areas covered: This review discusses the neurological and respiratory complications of SARS-CoV-2 infection and progresses to examine the role of the 'cytokine storm' and the involvement of TLR4 receptors in these complications. The possibility of using TLR4 modulators to curb the complications are considered and finally, ashort perspective on future potential drug treatments is offered. Various databases were searched including Pub-Med, Google Scholar, and Medline. The search mainly included research articles, meta-analysis, retrospective studies, reports, and systematic reviews.Expert opinion: TLR4 modulators are being investigated in clinical trials for COVID-19. Challenges in terms of structural diversity of the agents, their natural origin, and efficacy demand extensive research.

Keywords: Sars-cov-2; acute respiratory distress syndrome; coronavirus; covid-19; cytokine storm; neurological complications; tlr-4; toll-like receptors.

Publication types

  • Review

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use*
  • COVID-19 / complications
  • COVID-19 Drug Treatment*
  • Humans
  • Lung Diseases / complications*
  • Nervous System Diseases / complications*
  • Retrospective Studies
  • SARS-CoV-2 / isolation & purification
  • Toll-Like Receptor 4 / drug effects*

Substances

  • Antiviral Agents
  • Toll-Like Receptor 4